Difference between revisions of "Dasatinib (Sprycel)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - ": new" to ": New") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 13: | Line 13: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://packageinserts.bms.com/pi/pi_sprycel.pdf Dasatinib (Sprycel) package insert]<ref name="insert"></ref> | *[http://packageinserts.bms.com/pi/pi_sprycel.pdf Dasatinib (Sprycel) package insert]<ref name="insert"></ref> | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/dasatinib.aspx Dasatinib (Sprycel) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/dasatinib.aspx Dasatinib (Sprycel) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/dasatinib-patient-drug-information Dasatinib (Sprycel) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dasatinib-patient-drug-information Dasatinib (Sprycel) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/dasatinib-patient-drug-information Dasatinib (Sprycel) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dasatinib-patient-drug-information Dasatinib (Sprycel) patient drug information (UpToDate)]</ref> | ||
Latest revision as of 01:00, 29 June 2024
General information
Class/mechanism: Tyrosine kinase inhibitor of BCR-ABL, the SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Binds to multiple conformations of the ABL kinase.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Dasatinib (Sprycel) package insert[1]
- Dasatinib (Sprycel) patient drug information (Chemocare)[4]
- Dasatinib (Sprycel) patient drug information (UpToDate)[5]
History of changes in FDA indication
Chronic myeloid leukemia
- 2006-06-28: Initial accelerated approval for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib. (Based on CA180-013)
- 2009-05-21: Converted to regular approval for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib. (Based on CA180-035)
- 2007-11-08: New accelerated approval for the treatment of adults with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy, including imatinib mesylate. The new dosing regimen is 100 mg taken orally once daily. (New dosing instruction; based on CA180-034)
- 2010-10-28: Accelerated approval for newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. (Approval expanded to the first-line setting; based on DASISION)
- 2015-08-12: Converted to regular approval for newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. (Based on DASISION)
- 2017-11-10: New indication for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. (Approval expanded to include the pediatric population; based on CA180-018 & CA180-226)
Ph+ ALL
- 2006-06-28: Initial approval for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. (Based on START-L)
- 2018-12-21: Approved for pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. (Based on COG AALL1122)
History of changes in EMA indication
- 2006-11-20: Initial authorization
History of changes in Health Canada indication
- 2007-03-26: Initial notice of compliance with conditions
- 2009-11-19: Conditions were met
History of changes in PMDA indication
- 2009-01-21: Initial approval for the treatment of imatinib-resistant chronic myelogenous leukemia.
- 2009-01-21: Initial approval for the treatment of recurrent or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
- 2011-06-16: New additional indication and a new dosage for the treatment of chronic myelocytic leukemia.
Also known as
- Code name: BMS-354825
- Brand name: Sprycel
References
Categories:
- Drugs
- Oral medications
- Mutation-specific medications
- Bcr-Abl inhibitors
- BTK inhibitors
- KIT inhibitors
- PDGFR inhibitors
- SRC inhibitors
- SYK inhibitors
- B-cell acute lymphoblastic leukemia medications
- Chronic myeloid leukemia medications
- Systemic mastocytosis medications
- EMA approved in 2006
- FDA approved in 2006
- Health Canada approved in 2007
- PMDA approved in 2009
- WHO Essential Cancer Medicine